Clinical Development of Siltuximab

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

(2014) Robert Z. Orlowski et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

(2014) J. San-Miguel et al.   BLOOD

Siltuximab: First Global Approval

(2014) Anthony Markham et al.   DRUGS

Exploiting interleukin 6 in multicentric Castleman's disease

(2014) Mark Bower et al.   LANCET ONCOLOGY

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Siltuximab for multicentric Castleman disease

(2014) Yi-Chang Liu et al.   Expert Review of Hematology

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

(2013) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

(2013) Sheeba K. Thomas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

(2013) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Multicentric Castleman’s Disease: A Challenging Diagnosis

(2013) Györgyi Műzes et al.   PATHOLOGY & ONCOLOGY RESEARCH

Surgery in Castlemanʼs Disease

(2012) Nadia Talat et al.   ANNALS OF SURGERY

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

(2012) Gary Hudes et al.   INVESTIGATIONAL NEW DRUGS

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

(2011) H. E. El-Osta et al.   ONCOLOGIST

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

(2010) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

(2010) T. Puchalski et al.   CLINICAL CANCER RESEARCH

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Castleman Disease

(2009) Danielle M. P. Cronin et al.   ADVANCES IN ANATOMIC PATHOLOGY